The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.
 
Thomas Marron
Consulting or Advisory Role - Abbvie; Arrowhead Pharmaceuticals; Astellas Pharma; AstraZeneca; Avammune; EMD Serono; Geneos; Merck; Regeneron; Replimune; Replimune; Storm Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
Travel, Accommodations, Expenses - Abbvie; Genentech
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Michael Gordon
Stock and Other Ownership Interests - Sphinx HS (previously CAREMISSION)
Consulting or Advisory Role - Deciphera; Imaging Endpoints; Morphic Therapeutic; OnQuality Pharmaceuticals; Qualigen Therapeutics; SpringWorks Therapeutics; Viracta Therapeutics
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Biosciences (Inst); Corcept Therapeutics (Inst); Deciphera (Inst); DynamiCure Biotechnology (Inst); Fore Biotherapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); ImaginAb (Inst); Merck Serono (Inst); NiKang Therapeutics (Inst); Nimbus Therapeutics (Inst); Novartis (Inst); OncoResponse (Inst); Pfizer (Inst); Pionyr (Inst); Plexxikon (Inst); Pyxis (Inst); Revolution Medicines (Inst); Riboscience (Inst); Shenzen Ionova (Inst); Sirnaomics (Inst); SQZ Biotech (Inst); Syndax (Inst); Theseus Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Application Serial No.: PCT/US24/27766 Filing Date: May 3, 2024 Title: Planet atmosphere gases enwrapped into composite nanomaterials with medical treatment applications
 
Christopher Chen
Consulting or Advisory Role - Boxer Capital; Globepoint Global
Research Funding - ADC Therapeutics (Inst); Gilead Sciences (Inst); Kinnate Biopharma (Inst); Mersana (Inst); ORIC Pharmaceuticals (Inst); Palleon Pharmaceuticals (Inst); Pionyr Therapeutics (Inst); Rain Oncology (Inst); Seagen (Inst); Takeda (Inst)
 
Jennifer Segar
No Relationships to Disclose
 
Aaron Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Ralph Boccia
Honoraria - Abbvie/Genentech; AstraZeneca; BeiGene; BMS; DSI; Genmab; Janssen; Sobi
Consulting or Advisory Role - BMS; Janssen
Speakers' Bureau - AstraZeneca; DSI; Janssen
Research Funding - Amgen (Inst); AstraZeneca (Inst); DSI (Inst); Genentech (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Daniel Johnson
Consulting or Advisory Role - Amgen; Daiichi Sankyo/Lilly; Nectin Therapeutics; Signalexis
Speakers' Bureau - AstraZeneca/MedImmune; Bristol-Myers Squibb/Pfizer; Merck
 
Jordan Berlin
Consulting or Advisory Role - Agenus; amplia; Astellas Pharma; Bayer Health; BeiGene; Bristol-Myers Squibb/Celgene; epsilon; insmed; ipsen; Mekanistic Therapeutics; Merck; Merck KGaA; Regeneron; Taiho Oncology
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); Nested Therapeutics (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Ipsen; Merck KGaA
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Won Jin Ho
Honoraria - Standard Biotools
Patents, Royalties, Other Intellectual Property - I hold patents and receive royalties from Rodeo Therapeutics.
 
Juergen Schanzer
Patents, Royalties, Other Intellectual Property - Vabysmo Patent Roche Diagnostics GmbH
 
Deepanwita Sengupta
Employment - DAAN Biotherapeutics (I); Pfizer; Riboscience
Stock and Other Ownership Interests - DAAN Biotherapeutics (I); Pfizer; Riboscience
Travel, Accommodations, Expenses - Pfizer
 
Ningwu Huang
Employment - Riboscience LLC
Stock and Other Ownership Interests - Riboscience LLC
 
Jeffrey Glenn
Employment - 4J Therapeutics, Inc.; Eiger InnoTherapeutics, Inc.; I-Cubed Therapeutics, LLC; Riboscience
Leadership - Eiger InnoTherapeutics
Stock and Other Ownership Interests - Eiger InnoTherapeutics
Consulting or Advisory Role - Eiger InnoTherapeutics
Patents, Royalties, Other Intellectual Property - related to disclosed founding entities
Travel, Accommodations, Expenses - Riboscience
 
Ildiko Csiki
Employment - Riboscience
Stock and Other Ownership Interests - Riboscience
Consulting or Advisory Role - Coherus Biosciences; Geneos
 
Klaus Klumpp
Employment - Riboscience LLC
Leadership - Riboscience LLC
Stock and Other Ownership Interests - Bioage; Riboscience LLC
Consulting or Advisory Role - Bioage; Riboscience LLC
Patents, Royalties, Other Intellectual Property - Riboscience LLC IP
 
Jamal Misleh
No Relationships to Disclose